← Leaderboards
Jarrod Mousa
University Of Georgia
$10,148,469
Attributed
$10,735,170
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,735,170 · 9
By mechanism
R01$7,777,363 · 4
R21$1,231,046 · 3
K01$1,044,753 · 1
R56$682,008 · 1
Top collaborators
- Eva-Maria Strauch3 shared
- Maria Cristina Gingerich2 shared
- Adam Wesley Barb1 shared
Most similar at University Of Georgia
Same institution · by research overlap
- Xiaorong Lin$11,480,457
- Richard Brian Meagher$7,686,733
Others in their field
Other Emerging Leaders on “Vaccines”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$149,372,007
- Kimberly Smith · Ppd Development Lp$115,671,664
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Yunda Huang · Fred Hutchinson Cancer Center$74,099,786
- Ted Ross · University Of Georgia$71,962,304
Research focus
VaccinesProteinsAntibodiesMonoclonal AntibodiesEpitopesBindingInfectionAntigensB-LymphocytesVirusPreventInnovationAcuteIn VivoImmune ResponseNeutralizing AntibodyTechnologyResponseCellsImmunologicsViralResearch PersonnelStructureHuman Monoclonal Antibodies
Grant awards (27)
An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV$688,268
R01 · FY2025 · AI · contact PI
Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection$684,721
R01 · FY2025 · AI · contact PI
Increasing the protective capacity of antibodies by enhancing Fc-mediated responses$416,276
R01 · FY2025 · AI
An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV$690,023
R01 · FY2024 · AI · contact PI
Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection$685,212
R01 · FY2024 · AI · contact PI
Antibody recognition of paramyxovirus surface proteins$682,008
R56 · FY2024 · AI · contact PI
A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)$201,900
R21 · FY2024 · AI
Computationally designed anchor scaffolds for elicitation of broadly neutralizing influenza antibodies$156,393
R21 · FY2024 · AI · contact PI
Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection$72,615
R01 · FY2024 · AI · contact PI
Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection$755,894
R01 · FY2023 · AI · contact PI
An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV$629,209
R01 · FY2023 · AI · contact PI
Structural and mechanistic insights into antibody neutralization of human metapneumovirus$518,147
R01 · FY2023 · AI · contact PI
Lymph node targeting nanoparticles for HIV Env proteins$221,848
R21 · FY2023 · AI · contact PI
Computationally designed anchor scaffolds for elicitation of broadly neutralizing influenza antibodies$201,480
R21 · FY2023 · AI · contact PI
A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)$156,975
R21 · FY2023 · AI
An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV$134,666
R01 · FY2023 · AI · contact PI
Structural and mechanistic insights into antibody neutralization of human metapneumovirus$53,480
R01 · FY2023 · AI · contact PI
Computationally designed anchor scaffolds for elicitation of broadly neutralizing influenza antibodies$40,378
R21 · FY2023 · AI · contact PI
Lymph node targeting nanoparticles for HIV Env proteins$5,172
R21 · FY2023 · AI · contact PI
Structural and mechanistic insights into antibody neutralization of human metapneumovirus$554,809
R01 · FY2022 · AI · contact PI
Lymph node targeting nanoparticles for HIV Env proteins$246,900
R21 · FY2022 · AI · contact PI
Structural and mechanistic insights into antibody neutralization of human metapneumovirus$612,945
R01 · FY2021 · AI · contact PI
Structural and mechanistic insights into antibody neutralization of human metapneumovirus$642,945
R01 · FY2020 · AI · contact PI
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection$348,251
K01 · FY2020 · OD · contact PI
Structural and mechanistic insights into antibody neutralization of human metapneumovirus$638,153
R01 · FY2019 · AI · contact PI
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection$348,251
K01 · FY2019 · OD · contact PI
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection$348,251
K01 · FY2018 · OD · contact PI